GRIT Bio Welcomes Jie Jia, Ph.D., as New Chief Operating Officer to Drive Global Mission

GRIT Bio Expands Leadership with Jie Jia as COO

Shenzhen GRIT Biotechnology Co., Ltd., recognized as a global leader in the realm of cell therapy, has made a significant strategic move by appointing Jie Jia, Ph.D., as its Chief Operating Officer (COO), effective immediately. This appointment reflects GRIT Bio's ambition to enhance its operational capabilities and extend its impact in the biopharmaceutical industry.

A Leader in Biopharmaceuticals

Dr. Jie Jia brings a wealth of experience, spanning over two decades, within the biopharmaceutical and healthcare sectors. His track record includes not only leadership roles but also pivotal contributions to the development and management of complex projects. Notably, Dr. Jia played a key role in establishing new operational frameworks and optimizing existing processes in his past scenarios, particularly during his tenure at CARsgen Therapeutics.

While at CARsgen Therapeutics, Dr. Jia was instrumental in transforming the company from its inception as a startup into a publicly traded entity through the successful launch of its U.S. operations. This significant milestone underlines his strategic insight and capacity for navigating the multifaceted challenges of the biopharmaceutical landscape.

Dr. Jia's academic credentials further enhance his qualifications for the role. He holds a Bachelor of Science in Biochemistry from Sichuan University, followed by a Ph.D. in Biochemistry and Molecular Biology from the Chinese Academy of Sciences. Furthermore, he has obtained a Postdoctoral Fellowship in Molecular Medicine from the Cleveland Clinic and an MBA focusing on Leadership and Digital Marketing from Youngstown State University.

Vision for Growth

In a statement regarding Dr. Jia's appointment, Dr. Yarong Liu, Chairman and CEO of GRIT Bio, expressed enthusiasm about his arrival: "We are thrilled to welcome Dr. Jia to our leadership team. His extensive experience and proven success in biotechnology and international market development perfectly align with the global vision of GRIT Bio. We believe his expertise will catapult our ongoing mission to innovate groundbreaking therapies for cancer patients."

Dr. Jia also shared his excitement, stating, "Joining GRIT Bio is an honor, and I look forward to collaborating with a talented team of scientists. Our proprietary cell therapy platforms have already yielded multiple distinctive TIL (tumor-infiltrating lymphocytes) projects with excellent potential. I'm eager to push forward these developments and foster collaborations that will shape the future of the company."

A Future of Innovation

Founded in 2019, GRIT Bio specializes in innovative biopharmaceutical solutions, particularly focusing on immune cell treatments for oncology. The company boasts a robust R&D pipeline for TIL therapies and has successfully concluded various rounds of equity financing backed by esteemed venture capitalists.

Among its flagship products, GT101 stands out as the first TIL therapy to enter registrational clinical trials, currently undergoing pivotal Phase II studies. The company is also progressing with GT201, the first TIL therapy utilizing a membrane-bound IL-15 complex, which has already received IND clearances in both the U.S. and China.

GRIT Bio maintains core R&D platforms including StemTexp®, StaViral®, ImmuT Finder®, and KOReTIL®, which are integral to developing cutting-edge therapies aimed at providing new hope to patients battling solid tumors. This strategic appointment of Dr. Jia as COO is anticipated to elevate the company’s capabilities and impact in potentially transforming cancer treatments.

For more information about GRIT Bio and its initiatives, visit www.grit-bio.com.